Bone density conservation agents

Related article: Osteoporosis and osteopenia

A variety of medications including the bisphosphonates have been touted to conserve or increase bone mass. These drugs have a number of side effects and are known or suspected to interfere with proper immune function.

Bisphosphonates

Bone has constant turnover, and is kept in balance (homeostasis) by osteoblasts creating bone and osteoclasts digesting bone. Bisphosphonates inhibit the digesting of bone by osteoclasts.

The bisphosphonate has a variety of side effects:1)

Those patients with elevated 1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol. – which is very common among those suffering from Th1 diseaseAny of the chronic inflammatory diseases caused by bacterial pathogens. – seem particularly predisposed to the adverse effects of dysregulated calcium metabolism.

All these meds have some effect on the immune or endocrine system and are, therefore, to be avoided.

Types of bisphopshonates

Other types of bone density conservation agents

===== Notes and comments =====

FDA Alert - Oral Bisphosphonates: Ongoing Safety Review - https://bit.ly/9EfpXY

===== References =====

1)
Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):75-84. doi: 10.1016/j.joms.2008.12.002.
[PMID: 19371818] [DOI: 10.1016/j.joms.2008.12.002]
2)
Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):144-8.
[PMID: 17627083]
3)
Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840-4.
[PMID: 8114238]
4) , 5)
Syntax error [pubmed plugin]